VIVUS (VVUSQ) Stock Price, News & Analysis

Company Overview

VIVUS, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for metabolic health, sleep-disordered breathing and sexual health. Headquartered in Redwood City, California, the company’s mission centers on addressing conditions with significant unmet medical needs by advancing novel treatment options. VIVUS is publicly traded on the OTC Markets under the ticker VVUSQ.

The company’s flagship product, Qsymia, combines phentermine and topiramate extended-release for chronic weight management in adults with obesity or overweight patients with weight-related comorbidities. Approved by the U.S. Food and Drug Administration in 2012, Qsymia marked VIVUS’s entry into the commercial marketplace and has since been licensed to partners for broader distribution. In the realm of sexual health, VIVUS in-licensed avanafil, marketed as Stendra, an FDA-approved therapy for erectile dysfunction, further diversifying its product portfolio and geographic footprint through strategic alliances.

In addition to its marketed products, VIVUS maintains a clinical pipeline aimed at addressing sleep apnea and other cardiometabolic disorders. The company collaborates with academic institutions and industry partners to explore novel mechanisms of action and delivery formats. Leveraging licensing agreements, VIVUS extends its reach across North America, Europe and key Asian markets while maintaining a lean corporate structure. Its leadership team comprises professionals with extensive experience in drug development, regulatory affairs and commercial strategy.

Key Stats

• Today's Range: $0.12 to $0.12
• 50-Day Range: $0.12 to $0.12
• 52-Week Range: $0.07 to $4.55
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VVUSQ Stock Analysis - Frequently Asked Questions

How have VVUSQ shares performed this year?

VIVUS's stock was trading at $0.1174 at the beginning of 2025. Since then, VVUSQ shares have increased by 0.0% and is now trading at $0.1174.

How do I buy shares of VIVUS?

Shares of VVUSQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:VVUSQ
• CIK: N/A
• Web: www.vivus.com
• Phone: 650-934-5200
• Fax: 650-934-5389
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A